Genmab AS (GEN):企業の財務・戦略的SWOT分析

◆英語タイトル:Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15903
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Genmab AS (GEN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company’s marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Its products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Mar 29,2019 Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
Mar 11,2019 Genmab names Marisol Peron as head of communications and investor relations
Feb 25,2019 Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
Feb 20,2019 Genmab 2018 annual report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Genmab A/S – Key Facts
Genmab A/S – Key Employees
Genmab A/S – Key Employee Biographies
Genmab A/S – Major Products and Services
Genmab A/S – History
Genmab A/S – Company Statement
Genmab A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Genmab A/S – Business Description
R&D Overview
Genmab A/S – Corporate Strategy
Genmab A/S – SWOT Analysis
SWOT Analysis – Overview
Genmab A/S – Strengths
Genmab A/S – Weaknesses
Genmab A/S – Opportunities
Genmab A/S – Threats
Genmab A/S – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Genmab A/S, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 29, 2019: Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
Mar 11, 2019: Genmab names Marisol Peron as head of communications and investor relations
Feb 25, 2019: Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
Feb 20, 2019: Genmab 2018 annual report
Nov 26, 2018: Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
Nov 14, 2018: Genmab reports financial results for the first nine months of 2018
Nov 01, 2018: Genmab Announces Data to be Presented at 2018 ASH Annual Meeting
Oct 29, 2018: Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
Oct 21, 2018: Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Genmab A/S, Key Facts
Genmab A/S, Key Employees
Genmab A/S, Key Employee Biographies
Genmab A/S, Major Products and Services
Genmab A/S, History
Genmab A/S, Subsidiaries
Genmab A/S, Key Competitors
Genmab A/S, Ratios based on current share price
Genmab A/S, Annual Ratios
Genmab A/S, Annual Ratios (Cont...1)
Genmab A/S, Interim Ratios
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Genmab A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Genmab A/S, Performance Chart (2014 - 2018)
Genmab A/S, Ratio Charts
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Genmab AS (GEN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bellvitge Biomedical Research Institute-製薬・医療分野:企業M&A・提携分析
    Summary Bellvitge Biomedical Research Institute (IDIBELL) is a research centre focused on cellular medicine. It conducts clinical and basic research for developing treatments and techniques to improve health care. IDIBELL carries its research work in the fields of cancer and human molecular genetics …
  • OXiGENE, Inc. (OXGN):企業の財務及び戦略的SWOT分析
    Summary OXiGENE, Inc. (Oxigene) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer and eye diseases. The company develops anti-vascular drugs such as vascular disrupting agents. It is developing a product for treatment of ovarian cancer, anaplastic thyroid cance …
  • Royal Mail plc:企業の戦略・SWOT・財務情報
    Royal Mail plc - Strategy, SWOT and Corporate Finance Report Summary Royal Mail plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Red Rock Resorts, Inc. (RRR):企業の財務・戦略的SWOT分析
    Red Rock Resorts, Inc. (RRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Kelda Group Ltd:企業の戦略・SWOT・財務分析
    Kelda Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Kelda Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Jinsung TEC Co., Ltd. (036890):企業財務及び戦略的SWOT分析
    Summary Jinsung TEC Co., Ltd. (Jinsung TEC) is a construction equipment manufacturer that designs and manufactures heavy construction equipment parts and other products. The company offers products such as roller, Idler and sprocket. Its roller offers track rollers and carrier roller. Jinsung TEC’s …
  • JustSystems Corporation (4686):企業の財務及び戦略的SWOT分析
    Summary JustSystems Corporation (JustSystems) is a software company that provides IT services. The company develops application and server software solutions. It offers products such as XML authoring, XML content management, and XML publishing. JustSystems offers solutions such as content management …
  • PUC Founder (MSC) Berhad (PUC):企業の財務及び戦略的SWOT分析
    Summary PUC Founder (MSC) Berhad (PUC Founder) is an investment holding company that offers services in areas such as media and advertising, e-payment services, and renewable energy. The company assists advertisers to build their brand and achieve their marketing objectives. It offers real one stop …
  • Oneness Biotech Co Ltd (4743):企業財務及び戦略的SWOT分析
    Summary Oneness Biotech Co Ltd (Oneness Biotech) is a biopharmaceutical company that conducts research and development of drugs. The company’s products include anti acne products. Its technologies include GAP cultivation platform, medicinal material identification, and separation and purification pl …
  • Ratnamani Metals and Tubes Ltd. (RATNAMANI):企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Ratnamani Metals and Tubes Ltd." The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric st …
  • Miller Energy Resources, Inc. (MILLQ):企業のM&A・提携動向(石油・ガス分野)
    Summary Miller Energy Resources, Inc. (Miller), formerly Miller Petroleum, Inc., is an oil and gas company that explores and produces oil and natural gas. The company operates primarily in four distinct fields in Alaska such as Redoubt Unit, West McArthur River (WMRU), North Fork Unit and Badami Uni …
  • Hangzhou Hikvision Digital Technology Co Ltd (002415):企業の財務・戦略的SWOT分析
    Hangzhou Hikvision Digital Technology Co Ltd (002415) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Reditus – SGPS SA (RED):企業財務及び戦略的SWOT分析
    Summary Reditus - SGPS SA (Reditus) is a technology company that offers software solutions. The company’s services and solutions comprise client services, IT infrastructure, SAP consulting, information security, enterprise content management, lean management, consulting, formation and development co …
  • TripAdvisor, Inc.:企業の戦略・SWOT・財務分析
    SummaryTripAdvisor, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • Tate and Lyle PLC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Tate and Lyle PLC Mergers and A …
  • Dell Inc.:企業の戦略・SWOT・財務情報
    Dell Inc. - Strategy, SWOT and Corporate Finance Report Summary Dell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Coherus BioSciences Inc (CHRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • Hard to Treat Diseases, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Hard to Treat Diseases, Inc. Me …
  • Wind Works Power Corp. (WWPW):企業のM&A・提携動向(エネルギー分野)
    Summary Wind Works Power Corp. (Wind Works) is a renewable energy company that develops wind energy projects. The company’s wind projects include Ganaraska Wind Park, Grey Highlands Wind Park, Settlers Landing Wind Park, Snowy Ridge Wind Park, Cloudy Ridge Skyway 126 Winds Park, Whispering Woods Win …
  • Teachers Insurance and Annuity Association of America (TIAA):企業の戦略・SWOT・財務情報
    Teachers Insurance and Annuity Association of America (TIAA) - Strategy, SWOT and Corporate Finance Report Summary Teachers Insurance and Annuity Association of America (TIAA) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆